Literature DB >> 9385591

Acute oral calcium-sodium citrate load in healthy males. Effects on acid-base and mineral metabolism, oxalate and other risk factors of stone formation in urine.

P O Schwille1, A Schmiedl, U Herrmann, R Schwille, E Fink, M Manoharan.   

Abstract

The currently preferred calcium preparations for supplementation of food vary widely with respect to calcium availability, effects on systemic mineral metabolism, acid-base status, and the calciuria-induced risk of urinary tract stone formation. In eight healthy males we studied the response to an acute load with alkali(sodium)-containing soluble calcium citrate (CSC) (molar ratio calcium/sodium/citrate approx. = 1/1/1), when taken in three different doses (10, 20, 30 mmol calcium) together with a continental breakfast. Intestinal calcium absorption, serum calcium, calcitonin, parathyroid hormone (PTH) other markers of bone metabolism, net acid excretion and calcium oxalate crystallization in urine were evaluated. CSC evoked a dose-dependent increase in calcium absorption, calcium in serum and urine, but no overt hypercalcemia, and calciuria was low relative to the excess calcium ingested; PTH fell and calcitonin rose (p < 0.05 vs. breakfast alone), but the diet-independent markers of bone resorption declined only insignificantly, while the markers of bone formation and turnover remained unchanged. There was a significant "once-daily" effect (= cumulative 24 h postload response) of CSC: a decrease in urinary cyclic AMP, phosphorus, and ammonium, and an increase in urinary bicarbonate. Soon after CSC intake, urinary calcium oxalate and hydroxyapatite supersaturation increased dose-dependently, the calcium oxalate crystal diameter was increased, but crystal aggregation time, which is crucial for stone formation, remained statistically unchanged. Thus, CSC provides calcium in a bioavailable form, creates mild systemic alkalinisation and inhibition of bone resorption, but leaves the risk of developing urinary stones unchanged. Comparative long-term studies on bone growth and the maintenance of bone health, using alkali-containing versus alkali-free calcium citrate, appear worthwhile.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9385591

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  4 in total

1.  Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo-controlled trial.

Authors:  Shameez Allie-Hamdulay; Allen L Rodgers
Journal:  Urol Res       Date:  2005-05-04

Review 2.  Citrate salts for preventing and treating calcium containing kidney stones in adults.

Authors:  Rebecca Phillips; Vishwanath S Hanchanale; Andy Myatt; Bhaskar Somani; Ghulam Nabi; C Shekhar Biyani
Journal:  Cochrane Database Syst Rev       Date:  2015-10-06

3.  Hypercalcemic crisis resulting from near drowning in an indoor public bath.

Authors:  Ryusaku Matsumoto; Go Yamada; Aya Amano; Tomoko Yamada; Keita Hamamatsu; Hiroyuki Murabe; Toshihiko Yokota
Journal:  Am J Case Rep       Date:  2013-06-19

Review 4.  Causal assessment of dietary acid load and bone disease: a systematic review & meta-analysis applying Hill's epidemiologic criteria for causality.

Authors:  Tanis R Fenton; Suzanne C Tough; Andrew W Lyon; Misha Eliasziw; David A Hanley
Journal:  Nutr J       Date:  2011-04-30       Impact factor: 3.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.